Here, BioSpace looks at seven indications ripe for GLP-1 expansion
The companys obesity portfolio also includes the Zealand Pharmapartnered amylin asset petrelintide, which last month underwhelmed investors with a 9% reduction in weight at 42 weeks In the Phase 2 ZUPREME-1 trial
Metabolic effects of L-carnitine supplementation during GLP-1 receptor agonist therapy: a case series
Semaglutide can cause fatigue in some individuals, especially early in treatment
The pulse it produces is sharp but brief, which is the single biggest practical limitation compared to modern alternatives
Here are foods to limit - Ohio State Health & Discovery, accessed April 22, 2025, GLP-1 Agonists and Lifestyle Adjustments | SheMed Blog, accessed April 22, 2025, What Should I Eat While Taking GLP-1 Medication